Citigroup - Mylan "buy"

Datum Erster Hoch Tief Schluss     Stücke Volumen
  14.11.13    30,935    30,935§30,935 30,935 € 200 6.187

GrB  

Mylan Launches First Generic Focalin XR® Capsules, 30 mg

13:35 18.11.13

PR Newswire

PITTSBURGH, Nov. 18, 2013

PITTSBURGH, Nov. 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Dexmethylphenidate Hydrochloride Extended-release (ER) Capsules, 30 mg, which is the first generic version of Novartis' Focalin XR®. Mylan was the first company to have filed a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV patent certification for Dexmethylphenidate Hydrochloride ER Capsules, 30 mg. The company received final approval from the U.S. Food and Drug Administration (FDA) for its ANDA for this product and was awarded 180 days of marketing exclusivity.

According to IMS Health, Dexmethylphenidate Hydrochloride ER Capsules, 30 mg, had U.S. sales of approximately $67.34 million for the 12 months ending Sept. 30, 2013. This product is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients age 6 years and older.

Currently, Mylan has 179 ANDAs pending FDA approval representing $90.5 billion in annual sales, according to IMS Health. Forty of these pending ANDAs are potential first-to-file opportunities, representing $24.1 billion in annual brand sales, for the 12 months ending June 30, 2013, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  18.11.13     42,31     42,44§41,51 41,806 $ 4.547.555 189 M

GrB  

RTK 41,86  $ RTP +0,13 EK 41,806 $ last shares 100 full realtime 3.531.458 peak 42,20 buran und MfG und danke und weitermachen
 

Mylan Announces Pricing of $2.0 Billion of Senior Notes

22:20 19.11.13

PR Newswire

PITTSBURGH, Nov. 19, 2013

PITTSBURGH, Nov. 19, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the pricing of a registered offering of aggregate principal amount of $2.0 billion in bond issuance comprised of:

   $500 million aggregate principal amount of 1.35% Senior Notes due 2016;
   $500 million aggregate principal amount of 2.55% Senior Notes due 2019;
   $500 million aggregate principal amount of 4.20% Senior Notes due 2023; and
   $500 million aggregate principal amount of 5.40% Senior Notes due 2043.

Mylan intends to use the net proceeds from the offering to fund the previously announced acquisition of the Agila Specialties business of Strides Arcolab (the "Agila Acquisition") and for general corporate purposes, including, but not limited to, repayment of short-term borrowings which may include repayment of borrowings under its revolving credit facility and accounts receivable securitization facility, and funding a previously announced buyback of our common stock of up to $500 million. Subject to customary closing conditions, the sale of the notes is expected to close on or about Nov. 29, 2013. Mylan continues to anticipate that it will complete the Agila Acquisition in the fourth quarter of 2013.

The offering may be made only by means of a prospectus supplement and a prospectus. A copy of the prospectus supplement and the prospectus relating to the offering will be filed with the Securities and Exchange Commission (the "SEC") and, when available, can be obtained from: (i) Merrill Lynch, Pierce, Fenner & Smith Incorporated at 222 Broadway, 11th Floor, New York, NY 10038, Attn: Prospectus Department, toll free at +1-800-294-1322 or at dg.prospectus_requests@baml.com; (ii) J.P. Morgan Securities LLC at 383 Madison Avenue, New York, NY 10179, Attn: Investment Grade Syndicate Desk, 3rd Floor, telephone collect at +1-212-834-4533; (iii) Morgan Stanley & Co. LLC at 180 Varick Street, New York, NY 10014, Attn: Prospectus Department, toll free at +1-866-718-1649 or at prospectus@morganstanley.com; (iv) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, toll free at +1-800-831-9146 or at batprospectusdept@citi.com; (v) Credit Suisse Securities (USA) LLC, at One Madison Avenue, New York, New York 10010, Attn: Prospectus Department, toll free at +1-800-221-1037; and (vi) Goldman, Sachs & Co.,  200 West Street, New York, NY 10282, Attn: Prospectus Department, toll free at +1?866?471?2526 or at prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities mentioned in this press release in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This press release includes statements that constitute "forward-looking statements," including with regard to the consummation of the offering described above and the anticipated use of proceeds therefrom. Consummation of the offering is subject to a number of conditions, some of which are beyond Mylan's control.  Therefore, no assurance can be given that the offering will be consummated on the terms described or at all, or that the proceeds will be able to be deployed as indicated. In addition, please refer to the cautionary statements and risk factors set forth in Mylan's Form 10-K for the fiscal year ended December 31, 2012, and Form 10-Q for the quarter ended September 30, 2013, and in its other periodic filings made with the SEC from time to time.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

Zeit  Kurs Stück
09:31:09 31,381 € 24
_________________
GRATULATION  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  25.11.13    31,381    32,606§31,381 32,606 € 99 3.199

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  25.11.13    31,305    32,215§31,305 32,215 € 20 644

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  25.11.13     31,36     32,20§31,36 32,20 € 12 386

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  25.11.13     42,75     44,37§42,63 44,22 $ 5.644.822 213 M

GrB  

Teva and Mylan Settle Copaxone® Patent Litigation in France, the UK and the Netherlands
14:05 25.11.13

PR Newswire

PITTSBURGH, Nov. 25, 2013

PITTSBURGH, Nov. 25, 2013 /PRNewswire/ -- Teva Pharmaceutical Industries (NYSE: TEVA) and Mylan Inc. (NASDAQ: MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone® (glatiramer acetate) in the United Kingdom, the Netherlands and France relating to non-infringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.

Quelle: PR Newswire  

Receive First Indian Biosimilar Regulatory Approval for Herceptin®
16:30 25.11.13

PR Newswire

PITTSBURGH, Nov. 25, 2013

PITTSBURGH, Nov. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche's Herceptin®, indicated for the treatment of HER2 overexpressing breast cancer. Mylan intends to market its trastuzumab product under the trade name Hertraz.

Mylan CEO Heather Bresch commented, "This regulatory achievement marks another Mylan first and underscores our commitment to, and confidence in, our biologic development program with Biocon and our belief that these products will become a global growth driver for Mylan over the long-term. We expect to launch our trastuzumab product in India early next year, marking our first launch of a biologic, and we look forward to bringing a high quality, affordable product to patients in India who need it. This launch also further strengthens our expanding commercial presence in India, as we enter the oncology and critical care segments."

Trastuzumab is one of the five biologic products Mylan is developing in partnership with Biocon for the global marketplace. Mylan has exclusive commercialization rights for biosimilar trastuzumab in the U.S., Canada, Japan, Australia, New Zealand and in the European Union and European Free Trade Association countries and co-exclusive commercialization rights with Biocon for product in India. Mylan expects to launch trastuzumab in India early in 2014.

According to IPSOS, trastuzumab had sales in India of approximately $21 million for the 12 months ended Dec. 31, 2012.

This press release includes statements that constitute "forward-looking statements," including with regard to product approvals and regulatory matters. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impact and effects of legal or regulatory proceedings; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.

Quelle: PR Newswire  

Zeit  Kurs Stück
  08:02:50§32,68 € 20
___________________
GRATULATION  

Zeit   Kurs Stück
  10:34:56§32,77 € 80
_________________
GRATULATION  

Give $1 Million to Nigeria for the Elimination of Mother-to-Child Transmission of HIV
14:05 01.12.13

PR Newswire

PITTSBURGH, Dec. 1, 2013

PITTSBURGH, Dec. 1, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading pharmaceutical companies, and the Elton John AIDS Foundation (EJAF) today announced that they will give a combined $1 million to the Business Leadership Council for a Generation Born HIV Free (BLC) for the elimination of mother-to-child transmission (eMTCT) of HIV in Nigeria.

Nigeria is home to 3.4 million people living with HIV, with approximately 60,000 children newly infected with the virus in 2012 alone – the most of any nation in the world.[1] For many years, the mother-to-child transmission rate there has remained at 30%[2], despite other countries – from the U.S. to Botswana – virtually eliminating mother-to-child transmission of HIV.

The global community, led by UNAIDS and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), has agreed on a Global Plan to eliminate mother-to-child transmission of HIV by the end of 2015. The plan's success depends on Nigeria, as it accounts for more than a quarter of all new infections.

In 2012, the BLC launched a partnership with the Government of Nigeria's Save One Million Lives team to catalyze data-driven, state-by-state operational plans, innovative policies and dedicated management capacity to facilitate scale up of eMTCT services in collaboration with other government entities and implementers. Their partnership has leveraged private sector resources to maximize the impact of funds already available for parts of the program like healthcare workers and medicines. The partnership was tested in Nasarawa state, which, under the leadership of the state government, PEPFAR, and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, tripled the number of women being tested for HIV and doubled the number of facilities offering eMTCT services. As a result, 80% of women who tested HIV-positive are now on treatment to prevent their children being born with the virus. The BLC, in collaboration with many other private funders, is now supporting the Save One Million Lives team within the Government of Nigeria to apply this successful model across a dozen more high-priority states.

The $1 million commitment by Mylan and EJAF will support this scale up effort through 2015, contributing to the national goal of testing 90% of pregnant mothers and treating those who are HIV-positive.

Mylan CEO Heather Bresch commented, "Mylan is proud to commemorate World AIDS Day by announcing this important partnership with EJAF and BLC to reach more HIV-positive pregnant women in Nigeria. Ending transmission of HIV from mother to child is an important step in ending AIDS. Mylan's mission is to provide the world's 7 billion people access to high quality medicine, and we have long been dedicated to ensuring access to affordable, life-saving antiretroviral medicines (ARVs). In fact, today approximately 40% of those being treated for HIV in developing countries rely on a Mylan product, and we have helped to dramatically reduce the cost of recommended ARV treatments. While Mylan and the entire generics industry have made significant contributions toward making ARVs more affordable, we believe the focus must now be on expanding access to treatment for more people, as it has been shown that treatment truly is prevention and the path to an AIDS-free future. With commitments like this one and our recent partnership to distribute point-of-care CD4 diagnostic tests, Mylan is doing more than ever before to fight AIDS."

Elton John commented, "For over a decade, I have been meeting women living with HIV who were desperate not to pass the virus to their unborn children. As soon as proven medication was available, my Foundation began to help expand national programs to prevent such transmission. Over the past three years alone, this funding has supported 693,631 expecting mothers across 600 sites in seven countries. These programs have proven highly successful, with 96% of mothers staying on life-saving ARV treatment during delivery, compared to a general population figure of just 66%. This means we have helped enable up to 65,000 children to be born HIV free. I am delighted that our fundraising collaboration with Mylan has expanded to a grant-making one, and look forward to us making a substantial contribution not only to reducing mother-to-child-transmission of HIV in Nigeria, but helping the world reach the target of elimination of this transmission by the end of 2015."

To fund this initiative, Mylan has donated $500,000 to EJAF, which will be matched dollar-for-dollar by EJAF, with total funding of $1 million going from EJAF to the BLC. The funding will initially target two of the 13 highest priority states for eMTCT in Nigeria – Plateau and Federal Capital Territory. The funds have been made immediately available to BLC in order that this work in support of the state governments and their partners can commence right away.

About EJAF

The Elton John AIDS Foundation is one of the largest private funding institutions for AIDS in the world. It was established by Sir Elton in 1992 with an office in New York that supports work in the Americas and the Caribbean and, a year later in 1993, with an office in London that supports programmes in Europe, Africa and Asia.  In 20 years, these combined offices have raised over £193m to support more than 1,400 projects across four continents.  Funding has helped leverage a further £250m for programme partners, enabling them to reach millions of people infected, affected or at risk of HIV. During 2012, the UK Foundation's support enabled over 150,000 people living with HIV to start medical treatment, and promoted HIV testing to 2.3m people in Africa. For more information go to: www.ejaf.com

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

About BLC

The Business Leadership Council for a Generation Born HIV Free is a private sector-led initiative with one goal: to end transmission of HIV from mothers to their children by the end of 2015. The BLC is committed to bringing a business mindset to this global effort, working behind the scenes to catalyze action that unblocks obstacles, amplifies the work of others, and drives a step change in the world's pace toward a generation born HIV-free. For more information go to: joinbornfree.org

[1] UNAIDS Report on the Global AIDS Epidemic 2013

[2] Ibid.

SOURCE Mylan Inc.

Quelle: PR Newswire  

to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.

Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  04.12.13    32,066    32,066§31,351 31,564 € 585 18.607

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  04.12.13    32,041    32,041§31,763 31,791 € 50 1.602

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  04.12.13     42,97     43,33§42,55 42,97 $ 4.118.180 177 M

GrB  

of Agila to Create Leading Global Injectables Platform
22:20 04.12.13

PR Newswire

PITTSBURGH, Dec. 4, 2013

PITTSBURGH, Dec. 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has completed the acquisition of the Agila injectables businesses from Strides Arcolab Limited (BSE: 532531, NSE: STAR) for up to $1.75 billion, which includes $250 million in contingent consideration. Since the initial announcement of this acquisition, the final transaction terms have been restructured to include provisions such as a hold back, or contingent consideration, of $250 million of the potential $1.75 billion total purchase price, which will be payable in whole or in part to Strides upon satisfaction of certain regulatory conditions, and an enhanced escrow arrangement to fund any potential regulatory remediation costs.

Separately and coincident with the closing of the Agila transaction, a number of key commercial enhancements have taken place that will reduce Agila's historic, long-term reliance on a business-to-business model and increase value to Mylan. These changes unlock commercial rights and economics in many of Mylan's key growth markets and improve the long-term commercial profile of Agila for Mylan. Some of these key changes include regaining full commercialization rights for most of Agila's U.S. portfolio, both marketed and pipeline products, including all oncolytics, and regaining significant product rights in Canada, Australia, Brazil, Japan and South Korea.

Mylan CEO Heather Bresch commented, "The acquisition of Agila will create a global injectables leader, expanding and strengthening Mylan's existing injectables platform and portfolio, and providing Mylan entry into exciting, new geographic markets. We believe we can generate significant growth from this business as we maximize the capabilities of this platform and accelerate the many untapped opportunities we see ahead."

Mylan President Rajiv Malik added, "The acquisition of Agila transforms Mylan into a global powerhouse in injectables research and development (R&D) and manufacturing, with four dedicated state-of-the-art R&D facilities staffed by more than 400 scientists and 13 dedicated manufacturing sites across six countries, and capabilities across all key technologies and product areas. Through this transaction, Mylan also has significantly expanded its injectable product portfolio, pipeline and capabilities, and today has more than 1,200 approved injectable products globally and more than 900 injectable products pending global approvals. Mylan expects to launch more than 800 injectable products through 2018, with approximately 150 of those in the U.S., across a broad range of therapeutic categories and delivery systems.

"Commercially, the combination strengthens Mylan's existing platform in developed markets, such as the U.S., where Mylan can now offer customers an even more comprehensive portfolio of high quality products. Unlocking commercial rights and economics in many of Mylan's key growth markets will provide us with additional opportunities to maximize these portfolios. Further, we have accelerated our expansion into key rest-of-world markets, including Brazil, India and Southeast Asia."

Mylan also announced that its board of directors has set Friday, April 11, 2014 as the date for its Annual Meeting of Shareholders.

Mylan Executive Chairman Robert J. Coury commented: "We are very excited to welcome Agila's employees to Mylan. It is clear that the Agila team brings to Mylan a true passion for their business and a strong work ethic, and we are confident they will contribute significantly to our future. I believe that, together, we will be able to integrate our businesses seamlessly and efficiently, and we are hitting the ground running with this process. Additionally, as we plan for 2014 and the integration of this business, we are pleased to have set the date for our Annual Shareholders' Meeting, which will take place on April 11, 2014."

This press release includes statements that constitute "forward-looking statements," including with regard to the Company's future operations, its anticipated business levels, future earnings, planned activities, anticipated growth, and other expectations and targets for future periods. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and often may be identified by the use of words such as "may," "believe," "anticipate," "expect," "plan," "estimate," "target" and variations of these words or comparable words. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: challenges, risks and costs inherent in business integrations and in achieving anticipated synergies; the effect of any changes in customer and supplier relationships and customer purchasing patterns; regulatory compliance status; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the Company's business; uncertainties and matters beyond the control of management; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with GAAP and related standards or on an adjusted basis. These forward-looking statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the Company or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary note on forward-looking statements and risk factors set forth in the Company's Report on Form 10-K, for the year ended Dec. 31, 2012, and in its other filings with the SEC. The Company undertakes no obligation to update statements herein for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.

Quelle: PR Newswire  

Zeit    Kurs Stück
  14:49:48§32,177 € 150
  14:32:42§31,773 € 199
  14:29:59§31,72 € 221
  11:56:32§31,72 € 80
_________________
GRATULATION  

RTK 43,64  $ RTP +0,67 EK 43,35 $ last shares 100 full realtime 581.210 peak 44,09

buran und MfG und danke und weitermachen  

PR Newswire

PITTSBURGH, Dec. 5, 2013

PITTSBURGH, Dec. 5, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Cabergoline Tablets USP, 0.5 mg, had U.S. sales of approximately $41.67 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

Currently, Mylan has 178 ANDAs pending FDA approval representing $90.3 billion in annual sales, according to IMS Health. Forty of these pending ANDAs are potential first-to-file opportunities, representing $24.1 billion in annual brand sales, for the 12 months ending June 30, 2013, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.

Quelle: PR Newswire  

Healthcare Conference
19:05 02.01.14

PR Newswire

PITTSBURGH, Jan. 2, 2014

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 32nd Annual Healthcare Conference on Tuesday Jan. 14, 2014, in San Francisco.

The presentation is scheduled to begin at 7:30 p.m. ET on Tuesday Jan. 14, 2014.  Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://investor.mylan.com/. An archived version will also be available following the live presentation and can be accessed at the same location for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire  

Mylan Launches Generic Detrol® LA Capsules
20:30 07.01.14

PR Newswire

PITTSBURGH, Jan. 7, 2014

PITTSBURGH, Jan. 7, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release (ER) Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol® LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Tolterodine Tartrate ER Capsules had U.S. sales of approximately $571.5 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

Currently, Mylan has 188 ANDAs pending FDA approval representing $94 billion in annual sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $24.1 billion in annual brand sales, for the 12 months ending June 30, 2013, according to IMS Health. When including ANDAs associated with Mylan's recent acquisition of Agila, the company now has a total of 287 ANDAs pending FDA approval.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.


Quelle: PR Newswire